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Study of the cerebral infarctions were embolic strokes of cardiac origin, 56% of which were caused by NVAF (2) . Atrial fibrillation (AF) increases in incidence with increasing age. Kuramoto et al reported that 10%of all autopsied patients had chronic AF, 7% had paroxysmal AF, most of which were non-rheumatic AF or NVAF (3) . Approximately 35%of patients with AFwill experience an ischemic stroke during their lifetime. Aberg indicated that 42% of autopsied AF patients without valvular or congenital heart diseases had systemic embolism, half of which were brain embolism (4) . Twenty-two percent of the AF patients had large cerebral infarctions, and 15%had medium-sized cortical infarctions at the autopsy (3). NVAF is an important cause offatal massive cerebral infarctions in the elderly. Approximately half of the patients with fatal massive cerebral infarctions whodied within 2 weeks after the strokes had embolic infarctions due to NVAF(5).
Prophylactic therapy for the prevention of recurrent embolic stroke
Cardiogenic embolic brain infarctions recur frequently. S age and Uitert reported the high risk of recurrent cerebral infarctions over the long-term in NVAFstroke patients who had no anticoagulant therapy (6). From an autopsy study, we indicated frequent recurrences in embolic strokes over the long-term with NVAF(7). Although the risk of early recurrences is well known in cerebral embolism of cardiac origin, these data show that the late recurrencesare also importantand suggest that long-term prophylactic therapy should be considered for the prevention of recurrent embolicstrokes in patients with NVAF.
The optimal time to initiate anticoagulation following a cardioembolicstroke continuesto be controversial. Immediate anticoagulation starting within 24-houror a fewdays after the embolicstroke reducesthe early recurrenceof embolism, but can sometimes induce brain hemorrhage or conversionof ischemic to hemorrhagic infarction. The Cerebral Embolism TaskForcestated that "withholdinganticoagulationfor several weeksin all patients or in those with nonrheumatic AFis a more conservative, but acceptable alternative approach(8). Our study indicated that long-term anticoagulant therapy (warfarin) preventedthe recurrentembolic brain infarction withoutmajorhemorrhagic complicationsevenin the elderly patients with NVAF(9). Although hypertension is the most important predisposing condition for cerebral hemorrhageand the risk of hemorrhagiccomplicationsrises with increasing intensity of anticoagulation, major hemorrhagiccomplications can be reducedif bloodpressure is kept within the normalrange andthe adequatetherapeuticanticoagulationis maintained. The EuropeanAFTrial Study Groupshowedthat the optimal intensity of anticoagulationwasbetweenan international normalized ratio (INR) of 2.0 and an INRof 3.9 (10) . Canantiplatelet therapy (aspirin) preventthe recurrent embolic infarction in NVAFpatients? The European AFTrial Study Groupindicated that anticoagulant therapy waseffective in reducingthe risk of recurrentvasculareventsin nonrheumatic AFpatients with a recent TIAor minorischemicstroke, but aspirin was less effective (Table 2) (1 1).
Primaryprevention for embolicstroke in NVAF All prospectivestudies revealeda reductionin the stroke rate for patients treated with warfarin and a small incidence ofmajor hemorrhagiccomplications. The CopenhagenAFASAK Study (12) indicated that the thromboembolic eventsand vascular mortality were significantly lower in the warfarin group than in the aspirin and placebo groups, whichdid not differ significantly (Table 3) . In this study, aspirin (75 mgper day) did not reducethe risk of thromboembolic complicationsin patients with nonrheumatic AF. The SPAFStudy (13) showed the reduction of stroke in aspirin therapy (325 mgper day), but it wasless effective than the warfarintherapy. Adjusted-dose warfarin is highly efficacious for the prevention of ischemicstroke in patients with AF.However,this treatment carries a risk of bleeding and the needfor frequent medical monitoring. The SPAFStudy Group(14) compareda combinationof low-intensity, fixed-dosewarfarin plus aspirin with conventionaladjusted-dose warfarin in patients with AFat a high risk of stroke. Theresults showedthat low-intensity, fixed-dosewarfarinplusaspirin wasinsufficient for stroke prevention; adjusted-dose warfarin (target INR2.0-3.0) obviously reduced stroke.
Older ages, a history of hypertension, recent congestive leart failure, previous arterial thromboembolism, thrombus in ;he left atrium, enlarged left atrium and left ventricular dysfunc-;ion on the echocardiograms can be predictors of thromboem3olism in non-rheumatic AF or in NVAF. The reduction of embolic events associated with chronic anticoagulant therapy (warfarin) appears to outweigh the risks 3f hemorrhagic complication for patients with NVAF. Aspirin nay offer an alternative for patients whoare not good candidates for anticoagulation, but may be less effective.
